Arjun Goyal Biography and Net Worth

Arjun Goyal focuses on creating and investing in companies that translate groundbreaking science into innovative medicines. Arjun was formerly a managing director at Vida Ventures, a leading US-based life sciences venture capital firm with a ~$1.8 billion in AUM. Arjun also previously served as a director on the boards of Scorpion Therapeutics, Quanta Therapeutics, and Alterome Therapeutics and as a co-founder and director, Affini-T Therapeutics. Furthermore, he has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX), Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck & Co.), and Asklepios Bio (acquired by Bayer).

Before co-founding Vida Ventures in 2017, Arjun was a life sciences investor at 5AM Ventures. Arjun received his BSc in Medical Science, Diploma in French and his MBBS degree from the Universities of Melbourne and Oxford. He completed his postgraduate clinical training in Internal Medicine in Sydney. He received his MPhil in Bioscience Enterprise from University of Cambridge and his MBA from Harvard Business School. Arjun has received multiple awards for his work including the Advance Award for Technology & Entrepreneurship from the Australian Government. He serves on the Committee for the American Australian Association Education Fellowship and is on the Board of Advisors of the MS/MBA Life Sciences Program at Harvard Business School where also serves as a Venture Capital Advisor.

What is Arjun Goyal's net worth?: The estimated net worth of Arjun Goyal is at least $13.67 million as of May 16th, 2025. Goyal owns 462,585 shares of Centessa Pharmaceuticals stock worth more than $13,674,013 as of December 4th. This net worth estimate does not reflect any other investments that Goyal may own. Learn More about Arjun Goyal's net worth.
How do I contact Arjun Goyal?: The corporate mailing address for Goyal and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Arjun Goyal's contact information.
Has Arjun Goyal been buying or selling shares of Centessa Pharmaceuticals?: Arjun Goyal has not been actively trading shares of Centessa Pharmaceuticals during the last quarter. Most recently, on Friday, May 16th, Arjun Goyal bought 417,646 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $12.73 per share, with a total value of $5,316,633.58. Following the completion of the transaction, the director now directly owns 462,585 shares of the company's stock, valued at $5,888,707.05. Learn More on Arjun Goyal's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Mario Accardi (President of the Orexin Program), Karen Anderson (Chief People Officer), Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), Arjun Goyal (Director), David Grainger (Insider), Iqbal Hussain (General Counsel and Corporate Secretary), Aaron Kantoff (Director), Harris Rotman (Senior Vice President, Regulatory Affairs), Saurabh Saha (CEO), Gregory Weinhoff (Chief Business Officer), and Antoine Yver (EVP). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, Centessa Pharmaceuticals insiders bought shares 2 times. They purchased a total of 462,585 shares worth more than $5,866,686.94. In the last year, insiders at the sold shares 45 times. They sold a total of 973,366 shares worth more than $16,763,018.36. The most recent insider tranaction occured on November, 12th when CTO Tia L Bush sold 40,000 shares worth more than $1,040,000.00. Insiders at Centessa Pharmaceuticals own 7.1% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 11/12/2025.

Arjun Goyal Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/16/2025	Buy	417,646	$12.73	$5,316,633.58	462,585
5/15/2025	Buy	44,939	$12.24	$550,053.36	44,939

Arjun Goyal Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $29.56

$28.52

$29.74

50 Day Range

MA: $24.96

$22.12

$29.56

2 Week Range

Now: $29.56

$9.60

$29.99

Volume

666,153 shs

Average Volume

2,111,480 shs

Market Capitalization

$3.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.55